| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber; Cancer Institute, Boston, Massachusetts, 02115 [Y -T. T., K. P., L. C., M. A., R. S., R. B., T. H., D. C., N. M., P. R., N. C. M., C. M., K. C. A.]; Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115 [Y-T. T., K. P., L. C., M. A., R. S., R. B., T. H., D. C., N. M., P. R., N. C. M., C. M., K. C. A.]; and Research Division, Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215 [Y-H. T., C. R. K.]
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Integrins are 
/ß-heterodimeric membrane proteins that mediate cell adhesion to the ECM. Integrin ligand binding by ECMs induces cytoskeletal rearrangement and cell motility in a variety of cell types. In the absence of ß1 integrins, hematopoietic stem cells have impaired migration (2)
. Although integrin-mediated adhesion is necessary for tumor motility, it is not sufficient. In human MM cells, the integrin 4ß1 is one of the main adhesion receptors that mediate tumor cell binding to FN and vascular cell adhesion molecule (3
, 4)
. ß1-Integrin-mediated adhesion of MM cells to FN confers protection against drug-induced apoptosis (5
, 6)
and triggers nuclear factor 
B-dependent transcription, and secretion of the major MM growth and survival factor IL-6 (7)
. We demonstrated recently costimulation of human MM cells via vascular endothelial growth factor and ß1 integrin (8)
, supporting ß1 integrin inside-out signaling.
The IGF-I is a low molecular weight, single chain polypeptide of which the extensive local production is consistent with its mediating autocrine or paracrine growth, in addition to its more classical endocrine mechanism. IGF-I elicits its action on cells by binding to the IGF-IR, which consists of an - and ß-subunit heterodimer: ligand-dependent tyrosine kinase activity rests in the ß-subunit. We and others have shown that IGF-I is a potent growth and survival factor in human MM cells (9, 10, 11, 12, 13, 14)
. Specifically, IGF-I activates at least 2 distinct PI3-K and MAPK signaling pathways, leading to both proliferative and antiapoptotic effects (11, 12, 13, 14)
. The increased growth of these cells in the presence of IGF-I requires IGF-IR and can be blocked by a neutralizing IR3 mAb. IGF-I is also a BM stroma-derived chemoattractant factor for the murine 5T2 MM cells (15)
. To date, however, whether IGF-I plays a role in regulating human MM cell adhesion and migration within the BM microenvironment remains undetermined.
Cholesterol-rich microdomains of the plasma membrane, also termed lipid rafts, are implicated in the recruitment of essential proteins for intracellular signal transduction. Therefore, they provide signaling platforms to coordinate cellular adhesion (16 , 17) and transmembrane signaling (18 , 19) . In human adenocarcinoma MCF-7 cells, transient redistribution of IGF-IR from nonraft to raft was observed after IGF-I treatment (18 , 20) . Membrane compartmentalization between rafts and nonrafts is also required for T-cell activation (21) , and T-lymphocyte costimulation is mediated by reorganization of membrane raft microdomains (22) . Importantly, integrins are lipid raft associated (16 , 17 , 23) , although the functional relevance of this association remains undefined.
PI3-K and p125FAK have been implicated in integrin-mediated cell motility in breast cancer cells and smooth muscle cells triggered by IGF-I (24
, 25)
. Recent reports have demonstrated tyrosine phosphorylation of paxillin and p130cas, and association of Crk with p130cas after IGF-I stimulation in Swiss 3T3 cells (26)
, suggesting that IGF-I cross-regulates integrin-dependent signaling pathways. In addition, tumor cell metastasis is regulated by the functional cooperation between IGF-I signaling and integrin vß5, independent of tumor cell growth (27)
. These findings suggest that integrin ligation, in conjunction with cytokine activation, may play an important role in the dissemination of malignant tumor cells (27
, 28)
. Because there is a lack of studies of IGF-I/IGF-IR and its interaction with ß1 integrins in human MM cells, we in the present study investigated the effect of IGF-I on MM cell adhesion and migration, and defined IGF-I/IGF-IR-induced signaling pathways mediating these processes. We studied interactions between ß1 integrin and IGF-I signaling, and showed that cross-talk between downstream signals of integrin ligand binding and IGF-IR activation are essential for optimal MM cell adhesion and migration. Furthermore, we defined the functional significance of membrane raft patching of IGF-IR and ß1 integrin during attachment and transmigration of MM cells induced by IGF-I.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Reagents.
Human plasma FN and neutralizing anti-IGF-IR mAb IR3 were obtained from Oncogene Research Products (San Diego, CA). IGF-I was obtained from PeproTech Inc. (Rocky Hill, NJ). Blocking anti-ß1 integrin mAb and anti--actinin mAb were obtained from Chemicon (Temecula, CA); anti-pAKT and PD98059 were purchased from Cell Signaling Technology (Beverly, MA); anti-IRS-1, anti- p125FAK, anti-p85PI3-K, and anti-phosphotyrosine Ab (anti-pTyr, 4G10) were obtained from Upstate Biotechnology, Inc. (Lake Placid, NY); and anti-IGF-IR, anti-pERK, and anti-Src Abs for immunoblotting were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All of the other reagents were purchased from Sigma Chemicals (St. Louis, MO).
Cell Adhesion Assays.
Before adhesion, cell lines were starved overnight in RPMI 1640/0.5% BSA, without loss of viability. CD138+ patient MM cells were resuspended in RPMI1640/0.2%BSA (adhesion medium) and used directly after their isolation. Cells (5 x 106/ml) were labeled with calcein-a.m. (Molecular Probes, Eugene, OR) for 30 min at 37°C, washed, and resuspended in adhesion medium. Cells were stimulated with or without IGF-I at 0–400 ng/ml for 15 min and added to FN (20 µg/ml) -coated 96-well plates for 45 min. In some experiments, cells were incubated with IGF-I in the presence of 100 µM Arg-Gly-Asp (RGD), a peptide that mimics the FN-binding site and blocks binding of ß1 integrins to FN in vitro; or with Arg-Gly-Glu (RGE) as a control peptide. To identify the individual role of IGF-I/IGF-IR-signaling molecules mediating MM adhesion, labeled cells were washed, preincubated with or without blocking mAbs against IGR-1R and anti-ß1 integrin or inhibitors (wort, LY294002, cyt D, PD98059), and then treated with or without IGF-I (100 ng/ml). Treatments with these inhibitors alone produced no significant toxicity, evidenced by trypan blue exclusion at the end of experiments. Cells were then added in triplicate to FN-coated 96-well plates at 37°C for 45 min (MM cell lines) or 2 h (MM patient CD138+ cells), and unbound cells were removed by four washes with RPMI 1640. The absorbance of each well was measured using 492/520 nm filter set with a fluorescence plate reader (Wallac VICTOR2; Perkin-Elmer, Boston, MA).
Immunoblotting and Immunoprecipitation.
Serum-starved MM cells (5 x 106/ml) were treated with or without IGF-I (100 ng/ml) for indicated time intervals. Some cells were plated on dishes coated with FN (25 µg/ml) and then treated with or without IGF-I (100 ng/ml) for 10 min. Cell extracts and immunoblotting were performed as described previously (29)
. For immunoprecipitation, the extracts were precleared by incubation with 25 µl of normal rabbit IgG serum or normal mouse IgG serum, followed by incubation with primary Abs diluted in lysis buffer for 2 h at 4°C.
Determination of the Distribution of Proteins between the Detergent-soluble and -insoluble Fractions.
Serum-starved OPM6 cells (4 x 107/ml) were stimulated with IGF-I (100 ng/ml) for 0, 5, and 30 min before lysis in 200 µl of ice-cold buffer [1% Brij 58, 20 mM Tris (pH 7.5), and 150 mM NaCl with protease and phosphatase inhibitors; Ref. 30
]. Brij 58, like Triton X-100, is a relatively mild, nonionic detergent. Membrane lipid rafts are insoluble in nonionic detergents at low temperature. The lysates were centrifuged at 14,000 x g for 25 min at 4°C, and the resultant supernatant was the detergent-soluble fraction (S). The detergent-insoluble pellets were resuspended and sonicated briefly in lysis buffer supplemented with 0.5% SDS and 1% ß-mercaptoethanol. After centrifugation, the resulting supernatant was the detergent-insoluble fraction (I) of the cell, excluding the insoluble cytoskeletal fraction. This method separates proteins bound to membrane rafts (detergent-insoluble) from those that are not raft-associated (detergent-soluble; Refs. 18
, 30
). The proteins were either separated directly by 8% SDS-PAGE and then visualized by immunoblotting for IGF-IR, p85PI3-K, and Src, or were first immunoprecipitated with an anti-ß1 integrin mAb and then immunoblotted.
Copatching Experiments.
Membrane lipid raft aggregation or patching was performed as described previously (18
, 22)
. Serum-starved OPM6 cells, either treated with or without 100 ng/ml IGF-I for 10 min, were fixed in 2% paraformaldehyde for 20 min on ice, incubated with FITC-labeled cholera toxin B (FITC-CTx; 8 µg/ml) for 20 min, and then stained with either anti-ß1 integrin (10 µg/ml) or anti-IGF-IR at 4°C for 30 min. Primary Abs were additionally clustered by adding Alexa Fluor 568-conjugated secondary Ab for 30 min on ice. After three washes, cells were layered on glass coverslips, fixed in 4% formaldehyde in PBS, and mounted onto slides in antifade solution (Molecular Probes). Cells were visualized using a Zeiss model LSM410 confocal laser scanning microscope (Zeiss, New York, NY) equipped with an external argon-krypton laser (488 and 568 nm) to detect colocalization of IGF-IR (red) and GM1 (green), as well as ß1 integrin (red) and GM1 (green). Images of optical sections (512 x 512 pixels) were digitally recorded. The resulting images were processed using Adobe PhotoShop software (Mountain View, CA).
Actin Polymerization.
Serum-starved cells were treated with or without 100 ng/ml IGF-I, permeabilized, fixed, and stained in a single step by the addition of a 1-ml solution containing 0.1 mg/ml L-lysophosphatidyl-choline, 5% formaldehyde in PBS/1% BSA, and 5 units of Alexa Fluor 488 phalloidin (Molecular Probes). Cells were incubated for 20 min at 4°C, washed, and subjected to flow cytometry. F-actin content induced by IGF-I was expressed as a percentage of control by dividing the mean fluorescence intensity of cells at each time point to mean fluorescence intensity of the unstimulated cells at time 0.
Transmigration Assay.
Chemicon QCM 96-well migration assay (8-µm pore size with FN-coated filter; Chemicon) was performed using cells pretreated with indicated inhibitors for 60 min at 37°C. Cells (2 x 105/100 µl) were placed in the migration chamber, and 150 µl of adhesion medium with or without IGF-I (100 ng/ml) were added to the feeder tray. After 4-h incubation, 150 µl of lysis buffer/dye solution was added to each well of the feeder tray and incubated for 15 min. Plates were measured with a fluorescence plate reader using 480/520 nm filter set (Perkin-Elmer Life Sciences). Some serum-starved MM cell lines were preincubated for 1 h with or without mAbs against IGF-IR, ß1 integrin, and MOPC21 control IgG1, cyt D, as well as chx. Transmigration assays were also performed as described previously (29)
.
Statistics.
Data are mean ± SE. Statistical analysis used the Student t test, with P < 0.05 considered significant.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. IGF-I at 20–400 ng/ml, physiological achievable concentrations, was next used in dose-response adhesion experiments. IGF-I significantly enhanced cell adhesion in a dose-dependent manner, with maximal adhesion at 100 and 40 ng/ml of IGF-I for MM.1S (1.7–2.3 fold increase) and OPM6 (2.5–3 fold increase) MM cells, respectively (Fig. 1B)
. As shown in Fig. 1C
, inhibition of IGF-IR by IR3 mAb significantly decreased adhesion compared with control mAb: 55–63% versus 0% inhibition for IR3 mAb versus isotype control MOPC21 IgG. This confirms that IGF-I induces increased MM cell adhesion to FN via IGF-IR.
|
, anti-ß1 integrin mAb (5–20 µg/ml) and RGD peptide (100 µM) significantly decreased IGF-I-stimulated MM cell adhesion, whereas isotype control IgG and the mutant RGE peptide had no effect. In addition, pretreatment of MM cells with cyt D (0.5 µM), an inhibitor of actin filament polymerization, completely blocked IGF-I-induced adhesion, indicating that cytoskeletal proteins are involved in ß1 integrin-mediated MM cell adhesion induced by IGF-I.
|
. Tyrosine phosphorylation of IGF-IR was maximal within 2 min and decreased after 20 and 10 min in MM.1S and OPM6 cells, respectively, confirming receptor autophosphorylation and internalization induced by IGF-I. Tyrosine phosphorylation of IRS-1, association of IRS-1 with p85PI3-K, and phosphorylation of AKT were detectable within 2 min and persisted for at least 60 min (Fig. 3A)
. Phosphorylation of ERK1/2 was increased at 2 min and remained above basal levels after 60 min of IGF-I treatment. Importantly, anti-IGF-IR immunoprecipitates from cell extracts immunoblotted with anti-ß1 integrin mAbs demonstrated IGF-IR and ß1 integrin complex formation within 2 min. This interaction of ß1 integrin and IGF-IR was transient, occurring within 2 min and decreasing after 20 min of IGF-I treatment (Fig. 3A)
. Because PMA is a strong agonist for the adhesiveness of ß1 integrins and regulates attachment of cells to FN (31
, 32)
, we next prepared cell extracts from MM cells after 10-min treatment with PMA (100 nM) and IGF-I (100 ng/ml), and then immunoprecipitated with anti-ß1 integrin mAb. As shown in Fig. 3B
, IGF-IR was detected in anti-ß1 integrin immunoprecipitates after either treatment. In addition, pretreatment with IR3 mAb inhibits coimmunoprecipitation of ß1 integrin with IGF-IR (Fig. 3B)
. These data confirm that IGF-IR associates with ß1 integrin in MM cells and additionally suggest that these receptors may cross-regulate one another in response to IGF-I or PMA.
|
, IGF-IR and ß1 integrin are present mainly in the S fraction in serum-starved OPM6 before IGF-I treatment, but are primarily in the I fraction after IGF-I stimulation. p85PI3-K, one of the earliest substrates activated by the IGF-IR, is similarly induced in the I fraction. Thirty min after IGF-I stimulation, these proteins return from membrane rafts (I fraction) to nonrafts (S fraction), demonstrating the temporal sequence and dynamics of their association with membrane rafts and their functional role in mediating IGF-I-stimulated MM cell adhesion and subsequent migration. To confirm that proteins in I fraction had been separated from proteins in S fraction, we immunoblotted for Src using a pan-Src Ab. Because Src is associated exclusively with membrane rafts (33)
, constitutive expression of Src in the I fraction but not in the S fraction confirms the quality of the preparation (Fig. 4A)
. These data demonstrate that membrane rafts are essential for IGF-I/IGF-IR signaling (18
, 19)
, and additionally show IGF-I-induced migration of ß1 integrin from nonrafts to rafts on the cell membrane.
|
. However, stimulation with IGF-I increased ß1 integrin costained with CTx (yellow), indicating that IGF-I stimulates ß1 integrin and raft clustering in the cell membrane (Fig. 4B)
. In parallel, IGF-IR colocalization with CTx after IGF-I stimulation is even more distinct in IGF-I-treated versus control unstimulated cells (Fig. 4B)
. These results demonstrate the association of IGF-IR and ß1 integrin with membrane rafts after IGF-I stimulation in intact OPM6 MM cells. Furthermore, when lipid rafts were disrupted using methyl-ß-cyclodextrin (5 mM) to deplete cholesterol, IGF-I-induced adhesion was completely blocked to the baseline (data not shown). Conversely, replenishment with cholesterol (30 µg/ml) after methyl-ß-cyclodextrin treatment completely restores IGF-I-enhanced adhesion. Therefore, ß1 integrin-mediated adhesion induced by IGF-I depends on intact membrane rafts.
IGF-I Induces ß1 Integrin Interaction with Activated Signaling Proteins Localized at Sites of Focal Adhesion.
Because pretreatment with cyt D abrogates IGF-I-enhanced MM adhesion to FN (Fig. 2)
, we next asked whether IGF-I increased levels of F-actin in OPM6 cells. We observed that IGF-I triggers a rapid increase in the polymerization of F-actin; it is detected as early at 2 min, persists for at least 10 min, and decreases afterward (Fig. 5)
. The increased actin polymerization occurs during IGF-I-enhanced adhesion.
|
shows that maximum phosphorylation of p125FAK and paxillin is evident 10–20 min after IGF-I treatment. There is a time lag of at least 10 min between maximal IGF-IR and p125FAK/paxillin phosphorylation. The temporal dependence of phosphorylation may represent sequential events during IGF-I-controlled MM adhesion and migration. Conversely, IGF-IR blocking mAb IR3 inhibits the IGF-I-induced tyrosine phosphorylation of both p125FAK and paxillin (Fig. 6B)
. In the whole cell extracts, the IGF-IR ß subunit is clearly visible as Mr 97,000 band, and IR3 mAb blocks IGF-I stimulation of IGF-IR tyrosine phosphorylation and subsequent activation of p125FAK and paxillin (Fig. 6B)
.
|
-actinin, serum-starved OPM6 cells were cultured on FN-coated plates, and then treated with or without IGF-I for 10 min. Cell extracts were prepared for immunoprecipitation with anti-ß1 integrin mAb followed by immunoblotting with anti-p125FAK, anti--actinin, or anti-paxillin Abs. Fig. 6C
shows that ß1 integrin interacts with p125FAK, -actinin, and paxillin in OPM6 cells adherent to FN. The interaction between ß1 integrin and these focal adhesion proteins is not observed in cells adherent to PLL, which increases cell adhesion to plastics through nonspecific binding (data not shown). Importantly, the interaction of ß1 integrin with focal adhesion components is enhanced in OPM6 cells after treatment with IGF-I; by densitometric analysis, ß1 integrin coimmunoprecipitation with p125FAK (59%), -actinin (47%), and paxillin (62%) increases, compared with adhesion of untreated MM to FN (Fig. 6D)
. Fig. 6E
additionally shows that pretreatment with 0.5 µM cyt D for 30 min completely abrogates p125FAK/paxillin tyrosine phosphorylation induced by IGF-I and the baseline activation of these proteins in OPM6 cells adherent to FN. These data indicate that IGF-I cross-regulates activation of ß1-integrin signaling, including phosphorylation of p125FAK and paxillin.
Effects of Inhibitors of PI3-K and ERK on IGF-I-induced ß1 Integrin-dependent MM Adhesion and Transmigration.
Because IGF-I predominantly induces PI3-K/AKT and ERK1/2 pathways in MM.1S and OPM6 cells (Fig. 3A)
, we next determined whether these pathways mediate IGF-I-enhanced adhesion and transmigration of MM cells using PI3-K and ERK1/2 inhibitors. As shown in Fig. 7A
, pretreatment with PI3-K inhibitors LY294002 (25–50 µM) or wort (0.1–0.3 µM) for 1 h completely prevents IGF-I-induced MM adhesion to FN, whereas pretreatment with ERK1/2 inhibitor PD98059 has no effect. In the presence of LY294002 (25–50 µM), PD98059 does not additionally inhibit IGF-I-induced MM cell adhesion. Thus, IGF-I-induced MM adhesion depends on activation of PI3-K/AKT signaling. We also examined the effect of LY294002 on IGF-I-induced MM adhesion to uncoated, PLL-coated, or FN-coated plates. Preincubation of MM.1S and OPM6 cells with LY294002 (20–50 µM) completely abolishes the increased adhesion to FN induced by IGF-I (Fig. 7B)
. Importantly, treatment of MM cells with LY294002 (25 or 50 µM) does not affect cell viability or cell adhesion on uncoated or PLL-coated plates (Fig. 7B)
. These results demonstrate that IGF-I regulates ß1 integrin-mediated MM adhesion in a PI3-K-dependent manner.
|
. In contrast, pretreatment with PD98059 has little effect on IGF-I-induced MM transmigration, confirming that PI3-K/AKT is a key regulator in this process. In addition, pretreatment with IR3 mAb, cytD, and anti-ß1 integrin mAb abrogates IGF-I-induced MM transmigration (Fig. 8B)
. Interestingly, IGF-I-induced MM transmigration does not require de novo protein synthesis, because chx pretreatment (chx; 5 µg/ml) for 30 min does not significantly abrogate the increased MM transmigration induced by IGF-I.
|
IR3 diminishes IGF-I-induced adhesion (Fig. 9)
. Because we did not serum-starve freshly isolated CD138+ patient MM cells, IR3 mAb does not completely abolish IGF-I-induced adhesion to FN. It is likely that other factors in the serum, i.e., vascular endothelial growth factor, contribute to MM cell adhesion to FN.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
IR3 mAb blocks this response. Taken together, our results suggest that IGF-IR and ß1 integrin play coordinated roles in enhancing MM cell adhesion in the BM milieu, supporting the preclinical rationale for targeting IGF-I/IGF-IR in novel treatment strategies for MM. Our data extend a previous report of IGF-I as a chemoattractant in the mouse 5T2 MM model (15 , 34 , 35) to human MM cells, providing new insights into the role of IGF-I/IGF-IR in MM pathogenesis and clinical progression. This pleiotropic growth factor is produced in BM stromal cells, MM cells, osteoblasts, and endothelial cells in the BM milieu. Our results support a role for IGF-I in MM cell progression, as proposed in a recent clinical study showing that MM patients with higher serum IGF-I levels have inferior survival (36) .
Because IGF-I induces MM cell adhesion very rapidly, early IGF-IR signaling events could be decisive. IGF-I stimulation induces transient association between IGF-IR and ß1 integrin (Fig. 3)
, which is consistent with a previous report (37)
. This association could be either direct or via integrin-associated protein (38)
. Importantly, a blocking anti-ß1 integrin mAb completely blocks IGF-I-induced MM adhesion to FN, confirming a role for ß1 integrin in these processes. PI3-K/AKT activity is induced after IGF-I stimulation; and conversely, IGF-I-induced MM cell adhesion and migration is inhibited by LY294002 and wort. Moreover, expression of dominant-negative AKT using adenovirus vectors completely blocks IGF-I-induced MM adhesion and migration (data not shown). Therefore, PI3-K/AKT activity mediates IGF-I-induced MM cell adhesion and migration. In our previous study, LY294002 inhibits phosphorylation of AKT but not of ERK1/2 induced by sCD40L, suggesting that PI3-K and MAPK pathways are independent (13
, 29)
. Our present studies also indicate the independence of these two pathways. Interestingly, IGF-I-induced migration is not dependent on de novo protein synthesis, because cyclohexamide treatment has no effect on this response. The differential effects of sCD40L and IGF-I on migration may be attributable, at least in part, to differential activation of nuclear factor B and its target genes.
IGF-I induces an increase in actin polymerization, therefore enhancing interactions among integrin, cytoskeletal, and signaling components. It contributes, at least in part, to IGF-I-induced MM adhesion. Increasing evidence supports a role for IGF-IR in regulating focal adhesion molecules, and we show here that p125FAK is tyrosine phosphorylated and activated by IGF-IR. Paxillin, which associates with p125FAK and is tyrosine phosphorylated upon p125FAK activation, is also tyrosine phosphorylated after IGF-I stimulation of MM cells. Because phosphorylation of these focal adhesion molecules is triggered by ß1 integrin binding to FN, these results show that both IGF-I and ß1 integrin activate the focal adhesion pathway. These results confirm that activated IGF-IR rapidly associates with ß1 integrin after IGF-I treatment (Fig. 3, A and B)
, demonstrating the functional sequelae of costimulation of both receptors. Because there is a time lag between phosphorylation of p125FAK and paxillin, phosphorylation of p125FAK may be the initial event during cell adhesion, with subsequent paxillin phosphorylation followed by dephosphorylation of both molecules leading to cell migration. Furthermore, we observed enhanced phosphorylation of focal adhesion proteins after IGF-I treatment of MM cells adherent to FN-coated plates, which was completely abolished by cyt D (Fig. 7D)
. Taken together, our data define a role for IGF-IR in the regulation of focal adhesion proteins critical for MM cell adhesion and migration. In addition, these results are in concert with a recent study showing that IGF-I-induced tyrosine phosphorylation of focal adhesion proteins can be dissociated from the activation of the ERK pathway in Swiss 3T3 cells (26)
.
Segregation between raft and nonraft proteins in unstimulated cells localizes molecules during cell adhesion and migration. Our data indicate that IGF-I triggers clustering of membrane rafts, which coalesce into large domains. Moreover, recruitment of activated integrins into lipid rafts facilitates upstream cell signaling. Although ß1 integrins may associate with lipid rafts (16 , 17 , 39) , they may be restrained by cytoskeletal tethering in a manner that excludes them from lipid rafts under unstimulated conditions. In our study, ß1 integrin is located predominantly in the soluble fraction of lysates from unstimulated cells and stains mainly in the nonrafts of unstimulated cell membranes. IGF-I induces rapid and transient untethering of ß1 integrin from the cytoskeleton, its migration into membrane rafts, and its binding again to the cytoskeleton during MM cell adhesion and migration. Because IGF-I also stimulates actin polymerization, optimal interaction of ß1 integrin and activated focal adhesion signaling proteins is achieved to ensure these processes. These results demonstrate a complex dynamic sequence of events during cell migration induced by IGF-I in human MM cells, and confirm that cell adhesion is a prerequisite for cell migration. In addition, disruption of rafts by chemical depletion of membrane cholesterol impairs IGF-I-induced cell adhesion, confirming a role of membrane rafts in IGF-I/IGF-IR and ß1 integrin signaling. These functional sequelae of lipid rafts in MM cell adhesion are in concert with studies using T cells (16 , 21 , 22) and breast cancer cells (18 , 20) . Furthermore, Semac et al. (40) showed recently that Rituximab (mAb targeting CD20) in Burkitt lymphoma-derived Raji cells, by redistributing CD20 to rafts, modifies their stability and organization, thereby modulating associated signaling pathways and C’ defense capacity. Our study suggests that targeting IGF-I/IGF-IR using a humanized IGF-IR Ab or small molecule may have similar functional sequelae.
In conclusion, our study identifies a chemotactic effect of IGF-I on human MM cells mediated via activation of PI3-K/AKT and ß1 integrin. We demonstrate for the first time that membrane raft association with IGF-IR and ß1 integrin regulates MM cell adhesion and migration within the BM milieu. Importantly, these results suggest a role for IGF-I in MM disease progression and support targeting IGF-I/IGF-IR in novel MM treatment strategies.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported by a Multiple Myeloma Research Foundation Senior Research Award (Y-T. T., C. M., N. M., and T. H.), NIH Grants RO-1 50947 and PO1-78378, as well as the Doris Duke Distinguished Clinical Research Scientist Award and the Cure for Myeloma Fund (K. C. A.). 
2 To whom requests for reprints should be addressed, at Department of Adult Oncology, Dana-Farber Cancer Institute, M557, 44 Binney Street, Boston, MA 02115. Phone: (617) 632-2144; Fax: (617) 632-2140; E-mail: kenneth_anderson{at}dfci.harvard.edu
3 The abbreviations used are: MM, multiple myeloma; BM, bone marrow; IGF, insulin-like growth factor; IGF-IR, type-1 IGF receptor; FN, fibronectin; ECM, extracellular matrix; IRS-1, insulin receptor substrate-1; PI3-K, phosphatidylinositol 3'-kinase; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated mitogen-activated protein kinase; mAb, monoclonal antibody; cyt D, cytochalasin D; PMA, phorbol myristate acetate; PLL, poly-L-Lysin; wort, wortmannin; Ab, antibody; chx, cycloheximide; F-actin, filamentous actin.
Received 4/22/03. Revised 6/12/03. Accepted 7/ 3/03.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
activation. J. Biol. Chem., 277: 7875-7881, 2002.B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene, 21: 5673-5683, 2002.[Medline]
3ß1 and 6ß1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain OF CD36. J. Biol. Chem., 275: 35264-35275, 2000.-V-ß3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor. Proc. Natl. Acad. Sci. USA, 93: 2482-2487, 1996. v ß 5 to promote tumor cell dissemination in vivo. J. Clin. Investig., 99: 1390-1398, 1997.[Medline]
B signaling. Blood, 101: 2762-2769, 2003. v ß 3 affinity by increasing the amount of integrin-associated protein that is associated with non-raft domains of the cellular membrane. J. Biol. Chem., 277: 1800-1805, 2002.This article has been cited by other articles:
|
|
 |
|
  M. Fulciniti, P. Tassone, T. Hideshima, S. Vallet, P. Nanjappa, S. A. Ettenberg, Z. Shen, N. Patel, Y.-t. Tai, D. Chauhan, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma Blood, July 9, 2009; 114(2): 371 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-T. Tai, E. Soydan, W. Song, M. Fulciniti, K. Kim, F. Hong, X.-F. Li, P. Burger, M. J. Rumizen, S. Nahar, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells Blood, April 30, 2009; 113(18): 4309 - 4318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Legate, S. A. Wickstrom, and R. Fassler Genetic and cell biological analysis of integrin outside-in signaling Genes & Dev., February 15, 2009; 23(4): 397 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zong, C. C. Bastie, J. Xu, R. Fassler, K. P. Campbell, I. J. Kurland, and J. E. Pessin Insulin Resistance in Striated Muscle-specific Integrin Receptor {beta}1-deficient Mice J. Biol. Chem., February 13, 2009; 284(7): 4679 - 4688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. J. Becher, K. M. Peterson, S. Khatua, M. R. Santi, and T. J. MacDonald IGFBP2 Is Overexpressed by Pediatric Malignant Astrocytomas and Induces the Repair Enzyme DNA-PK J Child Neurol, October 1, 2008; 23(10): 1205 - 1213. [Abstract] [PDF]
|
|
|
|
|
|
Y.-T. Tai, M. Dillon, W. Song, M. Leiba, X.-F. Li, P. Burger, A. I. Lee, K. Podar, T. Hideshima, A. G. Rice, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu Blood, August 15, 2008; 112(4): 1329 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. U. Holt, U.-M. Fagerli, V. Baykov, T. B. Ro, H. Hov, A. Waage, A. Sundan, and M. Borset Hepatocyte growth factor promotes migration of human myeloma cells Haematologica, April 1, 2008; 93(4): 619 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Huston, X. Leleu, X. Jia, A.-S. Moreau, H. T. Ngo, J. Runnels, J. Anderson, Y. Alsayed, A. Roccaro, S. Vallet, et al. Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment Clin. Cancer Res., February 1, 2008; 14(3): 865 - 874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Leleu, X. Jia, J. Runnels, H. T. Ngo, A.-S. Moreau, M. Farag, J. A. Spencer, C. M. Pitsillides, E. Hatjiharissi, A. Roccaro, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia Blood, December 15, 2007; 110(13): 4417 - 4426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Pals, D. J. J. de Gorter, and M. Spaargaren Lymphoma dissemination: the other face of lymphocyte homing Blood, November 1, 2007; 110(9): 3102 - 3111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Edderkaoui, P. Hong, J. K. Lee, S. J. Pandol, and A. S. Gukovskaya Insulin-like Growth Factor-I Receptor Mediates the Prosurvival Effect of Fibronectin J. Biol. Chem., September 14, 2007; 282(37): 26646 - 26655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kobune, H. Chiba, J. Kato, K. Kato, K. Nakamura, Y. Kawano, K. Takada, R. Takimoto, T. Takayama, H. Hamada, et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism Mol. Cancer Ther., June 1, 2007; 6(6): 1774 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Alsayed, H. Ngo, J. Runnels, X. Leleu, U. K. Singha, C. M. Pitsillides, J. A. Spencer, T. Kimlinger, J. M. Ghobrial, X. Jia, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma Blood, April 1, 2007; 109(7): 2708 - 2717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fonseca and A. K. Stewart Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach Mol. Cancer Ther., March 1, 2007; 6(3): 802 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tohami, L. Drucker, H. Shapiro, J. Radnay, and M. Lishner Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential FASEB J, March 1, 2007; 21(3): 691 - 699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Triplett and F. M. Pavalko Disruption of {alpha}-actinin-integrin interactions at focal adhesions renders osteoblasts susceptible to apoptosis Am J Physiol Cell Physiol, November 1, 2006; 291(5): C909 - C921. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Shukla, X. Coumoul, L. Cao, R.-H. Wang, C. Xiao, X. Xu, S. Ando, S. Yakar, D. LeRoith, and C. Deng Absence of the full-length breast cancer-associated gene-1 leads to increased expression of insulin-like growth factor signaling axis members. Cancer Res., July 15, 2006; 66(14): 7151 - 7157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-T. Tai, X.-F. Li, I. Breitkreutz, W. Song, P. Neri, L. Catley, K. Podar, T. Hideshima, D. Chauhan, N. Raje, et al. Role of B-Cell-Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment. Cancer Res., July 1, 2006; 66(13): 6675 - 6682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Huang, H.-M. Shen, G. Shui, M. R. Wenk, and C.-N. Ong Emodin Inhibits Tumor Cell Adhesion through Disruption of the Membrane Lipid Raft-Associated Integrin Signaling Pathway Cancer Res., June 1, 2006; 66(11): 5807 - 5815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hideshima, L. Catley, H. Yasui, K. Ishitsuka, N. Raje, C. Mitsiades, K. Podar, N. C. Munshi, D. Chauhan, P. G. Richardson, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells Blood, May 15, 2006; 107(10): 4053 - 4062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-R. Shen, Y.-M. Hsu, K.-F. Hsu, Y.-F. Chen, M.-J. Tang, and C.-Y. Chou Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by {alpha}v{beta}3 integrin signaling Carcinogenesis, May 1, 2006; 27(5): 962 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. K. Lee, J. H. Lee, M. Kim, Y. Kariya, K. Miyazaki, and E. K. Kim Insulin-like Growth Factor-1 Induces Migration and Expression of Laminin-5 in Cultured Human Corneal Epithelial Cells. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 873 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Menu, H. Jernberg-Wiklund, T. Stromberg, H. De Raeve, L. Girnita, O. Larsson, M. Axelson, K. Asosingh, K. Nilsson, B. Van Camp, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model Blood, January 15, 2006; 107(2): 655 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Stromberg, S. Ekman, L. Girnita, L. Y. Dimberg, O. Larsson, M. Axelson, J. Lennartsson, U. Hellman, K. Carlson, A. Osterborg, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells Blood, January 15, 2006; 107(2): 669 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Han, F. R. Khuri, and J. Roman Fibronectin Stimulates Non-Small Cell Lung Carcinoma Cell Growth through Activation of Akt/Mammalian Target of Rapamycin/S6 Kinase and Inactivation of LKB1/AMP-Activated Protein Kinase Signal Pathways Cancer Res., January 1, 2006; 66(1): 315 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wlodarski, M. Kasprzycka, X. Liu, M. Marzec, E. S. Robertson, A. Slupianek, and M. A. Wasik Activation of Mammalian Target of Rapamycin in Transformed B Lymphocytes Is Nutrient Dependent but Independent of Akt, Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase, Insulin Growth Factor-I, and Serum Cancer Res., September 1, 2005; 65(17): 7800 - 7808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-T. Tai, X. Li, X. Tong, D. Santos, T. Otsuki, L. Catley, O. Tournilhac, K. Podar, T. Hideshima, R. Schlossman, et al. Human Anti-CD40 Antagonist Antibody Triggers Significant Antitumor Activity against Human Multiple Myeloma Cancer Res., July 1, 2005; 65(13): 5898 - 5906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sekimoto, J. Eipper-Mains, S. Pond-Tor, and C. M. Boney {alpha}v{beta}3 Integrins and Pyk2 Mediate Insulin-Like Growth Factor I Activation of Src and Mitogen-Activated Protein Kinase in 3T3-L1 Cells Mol. Endocrinol., July 1, 2005; 19(7): 1859 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kiely, M. Leahy, D. O'Gorman, and R. O'Connor RACK1-mediated Integration of Adhesion and Insulin-like Growth Factor I (IGF-I) Signaling and Cell Migration Are Defective in Cells Expressing an IGF-I Receptor Mutated at Tyrosines 1250 and 1251 J. Biol. Chem., March 4, 2005; 280(9): 7624 - 7633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Raje, S. Kumar, T. Hideshima, K. Ishitsuka, D. Chauhan, C. Mitsiades, K. Podar, S. Le Gouill, P. Richardson, N. C. Munshi, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma Blood, December 15, 2004; 104(13): 4188 - 4193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Podar, R. Shringarpure, Y.-T. Tai, M. Simoncini, M. Sattler, K. Ishitsuka, P. G. Richardson, T. Hideshima, D. Chauhan, and K. C. Anderson Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib Cancer Res., October 15, 2004; 64(20): 7500 - 7506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yanagisawa, K. Nakamura, and T. Taga Roles of lipid rafts in integrin-dependent adhesion and gp130 signalling pathway in mouse embryonic neural precursor cells Genes Cells, September 1, 2004; 9(9): 801 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Goel, M. Fornaro, L. Moro, N. Teider, J. S. Rhim, M. King, and L. R. Languino Selective modulation of type 1 insulin-like growth factor receptor signaling and functions by {beta}1 integrins J. Cell Biol., August 2, 2004; 166(3): 407 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Shaughnessy Jr Myeloma is on the move Blood, January 1, 2004; 103(1): 9 - 10. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
) or without IGF-I (100 ng/ml; 
), and added to FN-coated plates for the indicated times. After four washes, attached cells were quantified in a fluorescence analyzer. B, serum-starved MM.1S and OPM6 MM cells were labeled, washed, and incubated with 0–400 ng/ml of IGF-I for 15 min. The mixture was then added to FN-coated 96-well plates and incubated for an additional 45 min. C, MM.1S (
, 
) cells were preincubated with a neutralizing 
